
																
																	Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial
																
																
																
															Keywords: Pyridostigmine bromide; Sustained-release formulation; Muscarinergic side-effects; Myasthenia gravis; Therapy; Autoimmune disorder